Climb Bio Reports Progress in Clinical Trials for Budoprutug and CLYM116

Reuters01-08

<a href="https://laohu8.com/S/CLYM">Climb Bio</a> Reports Progress in Clinical Trials for Budoprutug and CLYM116

Climb Bio Inc. announced significant progress in its clinical development programs, with initial data from key trials expected in the second half of 2026. The company has dosed the first patients in the PrisMN Phase 2 trial of budoprutug, its anti-CD19 monoclonal antibody, for primary membranous nephropathy (pMN), and is continuing dosing in Phase 1b/2a trials for immune thrombocytopenia $(ITP)$ and Phase 1b in systemic lupus erythematosus $(SLE)$. Regulatory clearance was achieved for a SLE trial in China, with the first patient dosing anticipated in the first half of 2026. Additionally, the first subjects have been dosed in the Phase 1 healthy volunteer study of CLYM116, Climb Bio's anti-APRIL monoclonal antibody. Initial research results from these studies have not yet been presented but are expected to be reported in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9621889-en) on January 08, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601366419?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-08 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601366419","market":"nz","top_or_hot":-1,"title":"Climb Bio Reports Progress in Clinical Trials for Budoprutug and CLYM116","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CLYM\">Climb Bio</a> Reports Progress in Clinical Trials for Budoprutug and CLYM116\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Climb Bio Inc. announced significant progress in its clinical development programs, with initial data from key trials expected in the second half of 2026. The company has dosed the first patients in the PrisMN Phase 2 trial of budoprutug, its anti-CD19 monoclonal antibody, for primary membranous nephropathy (pMN), and is continuing dosing in Phase 1b/2a trials for immune thrombocytopenia <a href=\"https://laohu8.com/S/ITP\">$(ITP)$</a> and Phase 1b in systemic lupus erythematosus <a href=\"https://laohu8.com/S/SLE\">$(SLE)$</a>. Regulatory clearance was achieved for a SLE trial in China, with the first patient dosing anticipated in the first half of 2026. Additionally, the first subjects have been dosed in the Phase 1 healthy volunteer study of CLYM116, Climb Bio's anti-APRIL monoclonal antibody. Initial research results from these studies have not yet been presented but are expected to be reported in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9621889-en) on January 08, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Climb Bio Reports Progress in Clinical Trials for Budoprutug and CLYM116</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClimb Bio Reports Progress in Clinical Trials for Budoprutug and CLYM116\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-08 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CLYM\">Climb Bio</a> Reports Progress in Clinical Trials for Budoprutug and CLYM116\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Climb Bio Inc. announced significant progress in its clinical development programs, with initial data from key trials expected in the second half of 2026. The company has dosed the first patients in the PrisMN Phase 2 trial of budoprutug, its anti-CD19 monoclonal antibody, for primary membranous nephropathy (pMN), and is continuing dosing in Phase 1b/2a trials for immune thrombocytopenia <a href=\"https://laohu8.com/S/ITP\">$(ITP)$</a> and Phase 1b in systemic lupus erythematosus <a href=\"https://laohu8.com/S/SLE\">$(SLE)$</a>. Regulatory clearance was achieved for a SLE trial in China, with the first patient dosing anticipated in the first half of 2026. Additionally, the first subjects have been dosed in the Phase 1 healthy volunteer study of CLYM116, Climb Bio's anti-APRIL monoclonal antibody. Initial research results from these studies have not yet been presented but are expected to be reported in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9621889-en) on January 08, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210150020.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL9qc6WN:1","article_id":"2601366419","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601366419","pubTimestamp":1767873647,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Climb Bio Inc. announced significant progress in its clinical development programs, with initial data from key trials expected in the second half of 2026. The company has dosed the first patients in the PrisMN Phase 2 trial of budoprutug, its anti-CD19 monoclonal antibody, for primary membranous nephropathy , and is continuing dosing in Phase 1b/2a trials for immune thrombocytopenia  and Phase 1b in systemic lupus erythematosus . Regulatory clearance was achieved for a SLE trial in China, with the first patient dosing anticipated in the first half of 2026. Additionally, the first subjects have been dosed in the Phase 1 healthy volunteer study of CLYM116, Climb Bio's anti-APRIL monoclonal antibody. Initial research results from these studies have not yet been presented but are expected to be reported in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gene","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","BK4539":"次新股","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","CLYM":"CLIMB BIO INC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4585":"ETF&股票定投概念","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4139":"生物科技","NDAQ":"纳斯达克OMX交易所","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4588":"碎股","BK4112":"金融交易所和数据","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC"},"translate_title":"Climb Bio报告Budoprutug和CLYM116的临床试验进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLYM":0.9,"NDAQ":0.9},"content_text":"Climb Bio Reports Progress in Clinical Trials for Budoprutug and CLYM116\n    \n\n        Climb Bio Inc. announced significant progress in its clinical development programs, with initial data from key trials expected in the second half of 2026. The company has dosed the first patients in the PrisMN Phase 2 trial of budoprutug, its anti-CD19 monoclonal antibody, for primary membranous nephropathy (pMN), and is continuing dosing in Phase 1b/2a trials for immune thrombocytopenia $(ITP)$ and Phase 1b in systemic lupus erythematosus $(SLE)$. Regulatory clearance was achieved for a SLE trial in China, with the first patient dosing anticipated in the first half of 2026. Additionally, the first subjects have been dosed in the Phase 1 healthy volunteer study of CLYM116, Climb Bio's anti-APRIL monoclonal antibody. Initial research results from these studies have not yet been presented but are expected to be reported in 2026.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9621889-en) on January 08, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601366419","isCrawlerRequest":true}